HK Stock Market Move | INSILICO (03696) rose over 8% in early trading, with revenue exceeding 100 million US dollars in the first half of the year, confirming the commercial viability of "AI+Biotech".

INSILICO (03696) rose more than 8% in the morning session, up 8.03% to HK$43.04 as of press time with a trading volume of HK$4.11 billion. In terms of news, INSILICO recently released a profit announcement for the first half of the year, expecting revenue of approximately US$102.5 million to US$106.5 million, a year-on-year increase of about 272.7% to 287.3%; net profit is expected to be about US$33.5 million to US$39.5 million, with adjusted net profit forecasted to be about US$45.5 million to US$51.5 million. This performance was mainly attributed to the group's continued strategic initiatives to drive revenue growth and systematic improvement in operational efficiency. According to incomplete statistics, INSILICO has signed new heavyweight deals exceeding US$7 billion in total for 2026, of which more than US$175 million in down payments and milestone payments have been disclosed to be received in the near term, which is more than triple the revenue for 2025. Its AI pharmaceutical platform Pharma.AI has shortened the early research and development cycle from 4.5 years to 18 months, with 13 projects entering clinical trials. In terms of pipeline, the world's first AI-generated drug, Rentosertib, is advancing to Phase III. The $7 billion BD collaboration and platform ecosystem construction serve as dual engines, validating the commercial feasibility of "AI+Biotech".